# Plasmodium Immunotherapy for Lung Cancer

> **NCT02786589** · PHASE1,PHASE2 · UNKNOWN · sponsor: **State Key Laboratory of Respiratory Disease** · enrollment: 30 (estimated)

## Conditions studied

- Lung Cancer, Nonsmall Cell

## Interventions

- **BIOLOGICAL:** Blood-stage infection of P. vivax

## Key facts

- **NCT ID:** NCT02786589
- **Lead sponsor:** State Key Laboratory of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-27
- **Primary completion:** 2020-07-01
- **Final completion:** 2023-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02786589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02786589, "Plasmodium Immunotherapy for Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02786589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*